Copanlisib and Abametapir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordCopanlisib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Abametapir is a lotion used to treat head lice. Even though it goes on your scalp, a little gets into your body and can briefly slow down a liver enzyme called CYP3A4. That enzyme is one of the main ways your body breaks down copanlisib (Aliqopa), a cancer infusion medicine.
When that enzyme is slowed, copanlisib can build up higher than expected, which may raise the chance of side effects. The good news is this is easy to plan around. Your care team can space out the timing so the two don't overlap. Always tell your oncology team and pharmacist about any lice treatment before your infusion.
Mechanism: Abametapir is a CYP3A4 inhibitor; a single topical application can suppress CYP3A4 activity systemically. Copanlisib is a CYP3A4 substrate, so co-exposure predicts increased copanlisib AUC/Cmax and greater toxicity risk (hyperglycemia, hypertension, infection, myelosuppression).
- Direction: increased copanlisib exposure (inhibition; neither drug is a prodrug)
- Onset: rapid
- Evidence: theoretical, based on abametapir's known CYP3A4 inhibition
- Management: Avoid CYP3A4 substrates, including copanlisib, within 2 weeks of abametapir application. If concomitant use is unavoidable, avoid abametapir. Monitor for enhanced copanlisib effects if overlap occurs.
What happens
Increased exposure of CYP3A4 substrate
Interaction Deep Dive
For a period of 2 weeks following abametapir application, refrain from administering CYP3A4 substrates. Should this not be possible, abametapir itself should not be used 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by abametapir
How to manage this interaction
Both drugs can be used safely with planning. The key issue is timing.
- Keep taking your medications as prescribed and do not stop either on your own.
- The standard approach is to avoid CYP3A4 substrates like copanlisib for 2 weeks after applying abametapir. If that overlap can't be avoided, the alternative is to skip the abametapir lice treatment.
- Tell your oncology team and pharmacist before using any lice product so they can coordinate timing.
- If exposure does overlap, your team may monitor you more closely for copanlisib side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Copanlisib and Abametapir together?
Abametapir can slow how your body clears copanlisib, raising its levels, so avoid copanlisib for 2 weeks after applying abametapir. Coordinate timing with your oncology team and pharmacist. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Copanlisib and Abametapir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How is the Copanlisib and Abametapir interaction managed?
Both drugs can be used safely with planning. The key issue is timing. Keep taking your medications as prescribed and do not stop either on your own. The standard approach is to avoid CYP3A4 substrates like copanlisib for 2 weeks after applying abametapir. If that overlap can't be avoided, the alternative is to skip the abametapir lice treatment. Tell your oncology team and pharmacist before using… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Copanlisib or Abametapir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
Keep reading about Copanlisib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist